Provided herein are methods of producing an adeno-associated virus (AAV) product and methods of purifying adeno-associated virus. AAV is loaded onto an affinity resin, wash steps are undertaken, and AAV is eluted from the affinity resin. Various buffers are disclosed for use in the wash steps and elution.

A method for preventing obesity related to infection by an adipogenic adenovirus includes obtaining a sample from a person, assaying the sample to determine whether the person has been previously infected with an adipogenic adenovirus, and if the person has not been previously infected, providing the person with at least one sensor positioned to detect when a person's hand approaches a predetermined distance from the person's face. By warning the person of undesired hand-to-face contacts, the person is able to reduce the incidence of obesity related infections. Other embodiments are directed to a kit for preventing obesity caused by infection with an adipogenic adenovirus, such kit including a container for assaying an agent indicating the presence of antibodies to Ad-36, and a sensor positioned on an item selected from the group consisting of one of a hat, a writing instrument, eye glasses, a belt, sunglasses, a bra, a shirt, and a tie.

Diagnostic devices test markers for viral infection and markers for bacterial infection to effectively assist in the rapid differentiation of viral and bacterial infections, to differentiate between colonization and active infection, and to better diagnose microbiologically unconfirmed patients. In other embodiments, detecting a presence of MxA in combination with either the bacterial biomarker C-reactive protein or the bacterial biomarker procalcitonin increases the specificity of the bacterial biomarker with a concurrent improvement in sensitivity.

The present invention relates to protein NS2b or fragment(s) thereof as biomarker or diagnostic marker for the diagnosis and/or prognosis of Zika virus infections. The present invention further relates to peptides and cyclic peptides, compositions and arrays and multimer compounds comprising them. The present invention further relates to a method for the diagnosis and/or prognosis of Zika virus infections, comprising the use of protein NS2b or fragment(s) thereof, or of the peptides, cyclic peptides, compositions and/or arrays in immunoassays. The present invention further relates to peptide-based compounds comprising at least one fragment of protein NS2b and at least one further component and to methods for the diagnosis and/or prognosis of Zika virus infections.

Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample.

Methods, devices, systems, and kits for use in detecting and measuring infectious diseases are provided. In particular embodiments, methods, devices, systems, and kits for detecting and measuring Ebola virus, including Ebola Zaire strain virus, are provided. Devices and systems may be used within regions suffering from Ebola or other infections, providing local, rapid, and effective diagnosis of infectious diseases such as Ebola, improving treatment and reducing or preventing spread of such infectious diseases.

A method for diagnosing a limbic encephalitis, PNS, encephaloymyelitis, leukoencephalopathy, retinitis or optic atrophy, includes detecting a bornavirus in a sample, preferably from the group comprising mammalian 2 bornavirus, even more preferably VSBV-1, and mammalian 1 bornavirus, even more preferably BoDV-1; to a carrier containing a means for the capture of an antibody against at least one polypeptide selected from the group of BoDV-1-N, BoDV-1-P, VSBV-N and VSBV-P. A kit contains the carrier and a means for the detection of a captured antibody and a control for the detection of the presence of a sample. The carrier or kit or of a primer can be used for the detection of a bornavirus or a probe can be used for the diagnosis of an encephalitis, for the prognostication of post-transplantation complications, for the monitoring of a therapy of an encephalitis or of post-transplantation complications or for the differentiation between an autoimmune encephalitis and an encephalitis caused by infection.

This disclosure relates to novel peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use.

The present invention provides humanized antibodies against Enterovirus 71 (EV71), a causative agent of hand, foot, and mouth disease (HFMD), as well as pharmaceutical compositions comprising these antibodies and methods of their use in the treatment, prophylaxis, and diagnosis of HFMD. These antibodies are suitable for use in human subjects with HFMD or those at risk of HFMD, for example as a result of exposure to infected individuals.

A pathogen detection apparatus includes a collector that collects a pathogen in air; a reactor that causes the pathogen collected by the collector to react with a labeled substance; a time measurer that measures time from start of reaction in the reactor; a detector that detects a quantity of labeled substance that has reacted with the pathogen; and a controller. The controller calculates a gradient value on the basis of a predetermined time period from the start of reaction measured by the time measurer and the quantity of labeled substance detected by the detector, and determines, on the basis of the gradient value, a time interval to next collection that is to be performed by the collector.